AstraZeneca's Tagrisso trial confirms sustainable improvement in lung cancer progression April 18, 2018 Source: Sina Pharmaceutical A few days ago, AstraZeneca's latest test by Tagrisso (osimertinib) showed that the drug as a first-line treatment of lung cancer showed an "unprecedented progression-free survival benefit", and the efficacy showed continuous improvement during the treatment. Based on a new analysis of global phase III FLAURA trial data, the trial selected Tagrisso as a first-line treatment for locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive lung cancer patients, and evaluated the drug with EGFR tyrosine. Acid kinase inhibitor TKIs, erlotinib or gefitinib drugs control the difference in seizure effectiveness and safety. The results of the trial showed that patients treated with AstraZeneca Tagrisso had sustained progression-free survival (PFS) gain throughout the disease progression. The data obtained from the trial confirmed this, compared with patients in the EGFR-TKI, the proportion of patients in the Tagrisso group who stopped treatment was lower (77% vs. 49%), and patients in the Tagrisso group received follow-up treatment. The ratio is also higher (46% vs. 29%). The median time to first treatment or death in the first-line Tagrisso treatment group was 23.5 months, compared with 13.8 months in patients taking erlotinib or gefitinib. In addition, AstraZeneca pointed out that patients using Tagrisso as first-line treatment can reduce the incidence of secondary disease progression or death by half compared with the control group. AstraZeneca Chief Medical Officer Sean Bohen commented, "A new analysis from the FLAURA trial shows that the use of Tagrisso as a first-line treatment for lung cancer has a sustained effect and efficacy beyond follow-up treatment, which can almost reduce the risk of secondary disease progression or death in patients. These findings are based on the fact that Tagrisso has clinically demonstrated meaningful progression-free survival gains, which will greatly enhance the potential of the drug as a new therapeutic standard for the future.†The result of this analysis was recently held in Geneva in Europe. Released at the Lung Cancer Conference (ELCC). Lung cancer is the most common type of cancer worldwide and the leading cause of cancer deaths. Lung cancer deaths account for about one-third of all cancer deaths, exceeding the sum of breast cancer, prostate cancer, and colorectal cancer. It is estimated that EGFR mutations (EGFRm) are present in approximately 10%-15% of European and American NSCLC patients, and 30%-40% of Asian NSCLC patients. Most EGFRm-positive NSCLC patients develop resistance to existing targeted therapies (EGFR-TKIs) because of a secondary mutation called T790M, which usually recurs after about a year of treatment. There is a clear and urgent medical need for new treatment options in this area. Developed by AstraZeneca, Tagrisso is a third-generation oral irreversible EGFR-TKI that inhibits both the activating EGFR gene mutation and the EGFR function of the EGFR T790M resistance mutation. It also shows clinical efficacy for central nervous system tumor metastasis. The FDA has approved Tagrisso as a second-line therapy for NSCLC patients with EGFR T790M mutations that have continued to worsen after other EGFR-TKI therapies, and both Europe and the United States are currently evaluating their first-line treatment options. It is worth mentioning that Tagrisso is the first drug approved by the CFDA's priority review channel in the AstraZeneca pipeline. China's EGFR mutation rate is the highest in the world; the CFDA's approval of Tagrisso will provide Asilicon with a huge opportunity to bring a breakthrough therapeutic drug to the majority of lung cancer patients in China. (Sina Pharmaceutical Compilation / Fan Dongdong) Article reference source: AZ' Tagrisso offers sustained benefit in lung cancer Manual Massage Foot Spa Massager A manual massage Foot Spa Massager is a device designed to provide a relaxing and therapeutic foot massage. It is a manually operated handheld device, which means it does not require electricity or batteries to operate. The massager is made up of several parts, including the handle, rollers, and knobs. Manual Massage Foot Spa Massager,Portable Pedicure Tub,Bath Foot Massager,Foot Bath Machine Huaian Mimir Electric Appliance Co., LTD , https://www.mmfootspabath.com
To use the manual massage foot spa massager, you simply place your foot on a flat surface and apply the massager to the soles of your feet. The rollers and nodules stimulate the nerves and muscles in the foot, providing a deep tissue massage that helps relieve tension and pain.
The massager is small and lightweight, so you can easily take it with you wherever you go. It's also easy to clean, just wipe with a damp cloth after each use.
Overall, the Manual Massage Foot Spa Massager is a great option for those who are looking for an easy and effective way to relax and soothe their feet. It's affordable, easy to use, and can provide a range of health benefits, including improving circulation, reducing stress, and relieving foot pain and discomfort.